Insmed, Inc. (NASDAQ:INSM) Receives $205.41 Average Target Price from Analysts

Shares of Insmed, Inc. (NASDAQ:INSM) have earned an average recommendation of “Moderate Buy” from the twenty-four ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, twenty have given a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $205.4091.

INSM has been the subject of several analyst reports. Mizuho set a $212.00 price objective on Insmed in a research note on Thursday, December 18th. Jefferies Financial Group set a $269.00 price target on Insmed in a report on Wednesday, December 10th. Cowen set a $241.00 price objective on Insmed in a research note on Thursday, December 18th. Redburn Partners set a $263.00 price objective on shares of Insmed in a report on Thursday, December 4th. Finally, UBS Group upped their target price on shares of Insmed from $194.00 to $223.00 and gave the stock a “buy” rating in a research note on Friday, October 31st.

Insider Transactions at Insmed

In other Insmed news, insider Michael Alexander Smith sold 27,130 shares of the stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $183.78, for a total value of $4,985,951.40. Following the completion of the sale, the insider owned 54,902 shares in the company, valued at approximately $10,089,889.56. This trade represents a 33.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Elizabeth M. Anderson sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $204.58, for a total value of $1,022,900.00. Following the completion of the transaction, the director owned 58,729 shares in the company, valued at $12,014,778.82. The trade was a 7.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 157,829 shares of company stock worth $30,266,463. Company insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Insmed

Several large investors have recently made changes to their positions in the business. CIBC Private Wealth Group LLC boosted its holdings in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the last quarter. ORG Partners LLC raised its position in Insmed by 220.2% in the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 196 shares during the period. Hilltop National Bank purchased a new position in Insmed in the second quarter valued at about $28,000. Stone House Investment Management LLC bought a new position in shares of Insmed during the 3rd quarter valued at approximately $29,000. Finally, SBI Securities Co. Ltd. increased its stake in shares of Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 166 shares during the last quarter.

Insmed Stock Down 0.6%

Insmed stock opened at $175.79 on Tuesday. The firm has a market capitalization of $37.49 billion, a price-to-earnings ratio of -28.40 and a beta of 1.01. The firm’s fifty day moving average price is $188.71 and its two-hundred day moving average price is $145.88. Insmed has a 1-year low of $60.40 and a 1-year high of $212.75. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The business had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. During the same quarter in the prior year, the company earned ($1.27) EPS. The company’s revenue was up 52.4% on a year-over-year basis. On average, equities research analysts predict that Insmed will post -4.56 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.